<- Go Home
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Market Cap
$6.4M
Volume
1.5M
Cash and Equivalents
$7.0M
EBITDA
-$17.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$114.50
52 Week Low
$0.10
Dividend
N/A
Price / Book Value
1.12
Price / Earnings
-0.04
Price / Tangible Book Value
1.12
Enterprise Value
-$509.2K
Enterprise Value / EBITDA
0.03
Operating Income
-$17.1M
Return on Equity
2116.75%
Return on Assets
-219.28
Cash and Short Term Investments
$7.0M
Debt
$31.2K
Equity
$3.4M
Revenue
N/A
Unlevered FCF
-$8.4M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium